Description: Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM that is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM, which is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. It has an agreement with Region Östergötland for GMP process development of cell therapy for burn patients. Xintela AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Home Page: www.xintela.se
Medicon Village
Lund,
223 81
Sweden
Phone:
46 4 62 75 65 00
Officers
| Name | Title |
|---|---|
| Mr. Gregory Batcheller B.Sc., J.D., L.L.M., LLM | Executive Chairman of the Board |
| Dr. Evy Lundgren-Åkerlund Assoc.Prof, BSc, Ph.D. | Chief Executive Officer |
| Mr. Gunnar Telhammar | CFO & Finance Director |
| Ms. Lucienne Vonk | Chief Scientific Officer |
| Dr. Per Goran Oskar Norlen M.D., Ph.D. | Chief Medical Officer |
| Camilla Wennersten | Director of Clinical Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.9517 |
| Price-to-Sales TTM: | 38.7088 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 21 |